

Human bocavirus respiratory infection in infants in Córdoba, Argentina

Laura Moreno, M.D.,^a Leticia Eguizábal, M.D.,^a Lucía María Ghietto, M.D.,^b Elizabeth Bujedo, Biologist,^a and María Pilar Adamo, M.D.^b

ABSTRACT

It has been suggested that human bocavirus (HBoV) is related to acute respiratory infection (ARI) in children (prevalence: 0.9% to 33%) although clinical characteristics have not been clearly established yet.

Objectives. To identify the presence of HBoV in patients with ARI hospitalized in Hospital de Niños de Córdoba and describe cases without co-infection.

Method. HBoV screening was done by traditional PCR. Specimens to be screened were obtained from nasal secretions of 222 children under 2 years of age hospitalized due to an ARI during 2011. Demographic, clinical and radiological data were recorded.

Results. Fifteen HBoV+ patients (6.8%) were identified. Their median age was 3.5 months (range: 1-22), 7/15 in co-infection (5 respiratory syncytial virus, 1 parainfluenza-3, 1 Bordetella pertussis). Cases without co-infection: pneumonia 5/8, bronchiolitis 3/8; two required intermediate care, 7/8 oxygen therapy, 7/8 bronchodilators, 6/8 antibiotics; associated disease 1/8 (microcephalus/heart disease).

Conclusions. HBoV was identified in 15 out of 222 children (6.8%); the diagnosis of pneumonia was predominant without severe cases nor complications upon discharge.

Key words: human bocavirus, acute respiratory infection, pneumonia, infants.

<http://dx.doi.org/10.5546/aap.2014.eng.70>

INTRODUCTION

Acute respiratory infection (ARI) is a significant cause of infant morbidity and mortality.¹ Bronchiolitis and pneumonia are the main conditions that require hospitalization.

- Chair of Clinical Pediatrics, School of Medicine, Universidad Nacional de Córdoba. Hospital de Niños Santísima Trinidad, Córdoba.
- Institute of Virology J. M. Vanella, School of Medicine, Universidad Nacional de Córdoba.
- Immunology laboratory. Hospital de Niños Santísima Trinidad, Córdoba.

E-mail Address:

Laura B. Moreno, M.D.: lauramoreno@arnet.com.ar

Conflict of Interest: None.

Received: 04-03-2013

Accepted: 07-10-2013

Human bocavirus (HBoV), a parvovirus described by Allander, et al. has been recently added to the long list of microorganisms and viruses involved (2005).²

It has been shown that this virus has implications in wheezing³ and respiratory infections.⁴

Prevalence in children with respiratory disease is significantly different, ranging from 0.9% to 33% in various series.^{5,6} Locally, studies in symptomatic children and adults have shown variable frequencies (15% to 22%), according to the year they were registered.^{7,8} Besides, studies about seroprevalence revealed an immune response in all ages, indicating a wide distribution in the human population as well as an early incidence of the infection.⁹

Aiming at providing local epidemiological data on the presence of HBoV in our setting, we decided to estimate its prevalence in children younger than 2 years old hospitalized due to an ARI, and to describe the characteristics of positive cases without proven bacterial nor viral co-infection.

MATERIAL AND METHODS

Children younger than 2 years old hospitalized in Hospital de Niños de Córdoba because of community-acquired ARI (January-December, 2011) and whose parents accepted to participate were included in the study. The case history, clinical examination, chest X-ray, blood count/differential blood count were done and nasopharyngeal aspirate specimens were collected. Immunofluorescence (IF) tests were carried out for syncytial respiratory virus (SRV), parainfluenza (PIV) 1-2-3, influenza (FLU) A and B, adenovirus (AV) and human metapneumovirus (hMPV). A fraction (200 µL) of the supernatant was retained for HBoV search by traditional PCR and sequencing in compliance with a previously described protocol.^{7,8} *Bordetella pertussis* was investigated when it was appropriate and also

Collaborators: María Elena Suárez, M.D.,^a Constanza Polo, M.D.,^a Claudia Barreto, M.D.,^a Inés Marqués, M.D.,^b Liliana Mosca, M.D.,^c Patricia FerreyraSoaje, B.S.,^c and Daniel Quiroga, M.D.^b

common microorganisms were investigated in cases of pneumonia. X-rays were interpreted following standardized patterns: condensation or pleural effusion (pattern 1), interstitial infiltrates, interstitial and alveolar infiltrates, atelectasis (pattern 2), and normal X-ray or air trapping (pattern 3). Regardless of the study, patients were managed according to the treating physician's judgement. The protocol was approved by the hospital's Ethics Committee.

RESULTS

Two hundred and twenty two patients out of the total number (297) of patients who met the inclusion criteria were invited to participate, they signed the informed consent and completed the protocol requirements, including nasopharyngeal aspirate specimen collection (75%; 95% CI: 69-79). In 104 (46.8) of them some kind of respiratory virus was identified. Among virus detected by IF, SRV was the most predominant one, with

a detection rate of 48/222 (21.6%), followed by PI-3 virus with 23/222 (10.4%), hMPV with 10/222 (4.5%), Flu A with 6/222 (2.7%), and AV with 2/222 (0.9%). Fifteen HBoV+ cases were identified by PCR (6.8%, all of them HBoV1) with an age range from 1 to 22 months (median 3.5; 64.3% <6 months). The sample characteristics are detailed in *Table 1*.

The population distribution by epidemiological week is presented in *Figure 1*; HBoV showed an endemic-epidemic behavior.

Seven of the 15 (46,7%) HBoV+ cases had co-infection (SRV 5, PI 1 V and *Bordetella pertussis*1). A 22 month old patient with previous associated disease (genetic syndrome / heart disease / microcephalus) had pneumonia without severe involvement nor complications (discharged at 6 days). *Table 2* sums up the characteristics of HBoV+ cases without identified co-infections nor associated diseases (selected to optimize the description of the condition). Most of the

TABLE 1. General characteristics of the studied population. It includes HBoV+ cases (with and without co-infection). Hospital de Niños de Córdoba, 2011 (n= 222)


	Total n= 222	HBoV+ n= 15
Age (months)*	6 ± 5 (1-24)	6 ± 6 (1-22)
Boys	108 (49%)	9
Previous associated disease	33 (15%)	1
Preterm newborn infant	23 (10%)	2
History of recurrent wheezing	75 (34%)	7
Family history of asthma	22 (10%)	1
Exclusive maternal breastfeeding (6 months)	123 (55%)	9
Smoking in the household	48 (22%)	4
Symptomatic cohabitant	26 (12%)	3
Attending a day-care center	6 (3%)	0
Prodromal days*	3.5 ± 2 (1-10)	3 ± 2 (1-9)
Hospitalization days*	8.5 ± 5 (2-21)	9 ± 5 (2-21)
Days with oxygentherapy*	4 ± 5 (0-19)	4 ± 5 (0-19)
IMCU requirement	74 (33%)	5
ICU requirement/complications/death	3 (1%)	0
Positive cases for respiratory virus by IF	104 (49%)	6
Positive cases for <i>Bordetella pertussis</i>	13 (6%)	1

*Average ± SD (range). **n (%).

IMCU: Intermediate Care Unit.

ICU: Intensive Care Unit.

FIGURE 1. Case distribution by epidemiological week. Hospital de Niños de Córdoba, 2011 (n= 222)



IF: immunofluorescence (diagnostic panel for respiratory syncytial virus, influenza, parainfluenza, adenovirus and metapneumovirus).

TABLE 2. Characteristics of HBoV+ cases without proven co-infection. Hospital de Niños de Córdoba, 2011

	Case A	Case B	Case C	Case D	Case E	Case F	Case G
Age (months)	3	9	14	11	1	2	1
Sex	M	F	M	M	M	F	F
Month	March	April	May	June	June	August	August
Symptomatic cohabitant	No	No	No	No	Yes	No	Yes
History	Prematurity	RoB	RoB	RoB	No	No	No
Family smoking	Yes	No	No	No	No	Yes	No
Prodromal (days)	1	2	1	1	1	7	5
Hospitalization (days)	8	6	5	7	7	2	4
White blood cell/mL	16 000	14 500	15 800	14 600	10 000	10 140	15 300
Band cells (%)	1	0	0	0	0	1	1
Polynuclear leukocytes (%)	22	75	79	71	53	34	32
Absolute neutrophils (per mL)	3520	10 850	12 482	10 366	5300	3549	4052
ESR (mm/1 h)	12	23	25	35	39	6	34
Chest X-ray (a MS description and pattern)	Infiltrates interstitial (pattern 2)	Infiltrates interstitial-alveolar (pattern 2)	Infiltrates interstitial-alveolar (pattern 2)	Infiltrates interstitial-alveolar (pattern 2)	Infiltrates interstitial-alveolar (pattern 2)	Air trapping (pattern 3)	Normal (pattern 3)
Oxygen therapy (days)	2	3	3	4	No	2	4
Mechanical respiratory assistance	No	No	No	No	No	No	No
Bronchodilators	Yes	Yes	Yes	Yes	No	Yes	Yes
IMCU requirement	No	No	Yes	Yes	No	No	No
Diagnosis upon discharge	Apnea/bronchiolitis	Pneumonia	Pneumonia	Pneumonia	Pneumonia	Bronchiolitis	Bronchiolitis
Complications/death	No	No	No	No	No	No	No

RoB: Recurrent obstructive bronchitis.

IMCU: Intermediate Care Unit.

patients had wheezing which required oxygen therapy (6/7) and bronchodilators (6/7). A patient with bronchiolitis developed apnea; the patient had a history of preterm birth (without pulmonary disease). Pneumonia with interstitial-alveolar infiltrates (pattern 2) in chest X-rays was predominant with little increase of temperature. Hemoglobin levels showed no pathological abnormalities for the age; no gastrointestinal symptoms nor skin manifestations were observed either. Most of the patients (6/7) were treated with antibiotics during hospitalization (ampicillin, clarithromycin, gentamicin). Two required intermediate care during 2 and 8 days, respectively; none required intensive care. From the comparative analysis among HBoV+ cases with and without co-infection, the only difference was observed in the length of stay (12 ± 6 versus 6 ± 2 ; $p = 0.018$).

DISCUSSION

The rate of HBoV detection was 6.8%, a little lower than that previously detected in Córdoba (15.9%, 24.6% and 28.2% in 2007, 2009 and 2010, respectively).^{7,8} This variability could be due to normal oscillations of the virus circulation, with periodic, higher magnitude outbreaks; the world bibliography reflects divergences based on the region and years analyzed.^{5,6} Although possible differences related to sample collection procedures (swab tests or, nasal or nasopharyngeal aspirate specimens) and the methodology used (traditional, real-time PCR) should be considered, local data regarding children hospitalized because of an ARI were obtained based on the detection of the viral genome by traditional PCR in nasopharyngeal aspirate specimens.

A significant proportion of cases involved newborn infants and infants under 6 months old without risk factors nor associated diseases, and this suggests an early incidence of the infection which might result in hypoxemia and the need of hospitalization. Other authors reported the detection of HBoV in newborn infants,¹⁰ what would argue the presence of maternal antibodies with effective protection in this age group.

The rate of co-infection (46%) is consistent with that published in all regions.¹¹ However, for a more accurate estimate, the same approach should be used for the detection of all the microorganisms and viruses involved given that PCR sensitivity is higher than IF sensitivity.

Taking into account that winter is the season

where circulating viruses are predominantly respiratory, the high co-infection rate with other viruses was initially attributed to seasonal co-circulation. However, other authors suggest that prolonged viral excretion or persistence in the respiratory mucosa, tonsils and lymph nodes could account for these findings.¹² This situation, together with the identification of the virus in asymptomatic individuals initially questioned the pathogenic role of HBoV. However, a strong correlation between the respiratory disease and the viral load ($>10^4$ DNA copies) has been shown, together with the detection of the virus with the highest prevalence (and in single infection) in asymptomatic subjects.^{11,12}

Considering the causative association of HBoV with respiratory diseases, Meriluoto, et al.,¹³ followed up 109 newborn infants up to their adolescence and noticed an association between the primary infection (documented by serum viral load, IgM and IgG seroconversion) and respiratory disease (high and low), which predominantly occurred in children younger than 2 years old. Conversely, in cases of re-infection no respiratory symptoms were associated.

From the clinical and epidemiological standpoint, in cases without evidence of co-infection, the diagnosis of pneumonia was predominant, with infiltrates characteristic of viral conditions in the chest X-ray and very few cases of high temperature.¹⁴ Although they required oxygen therapy and bronchodilators, none needed mechanical ventilation nor had complications. Clinical features were similar to other respiratory viroses in this age group.⁴ Antibiotic use was 75%, a situation frequently observed in younger infants with pneumonia.¹⁵ It is worth mentioning that results in HBoV detection were available to treating physicians only after discharge.

At present, HBoV is considered a prevalent respiratory pathogen in children younger than 2 years old and in the market there is equipment for the molecular diagnosis of a wide panel of respiratory microorganisms and viruses, among which HBoV is included (Film Array Respiratory Panel [RP] made by Idaho Technology Inc, xTAG Respiratory Viral Panel FAST, by Luminex, Seeplex RV15 ACE Detection, by Seegene).

This article provides information regarding HBoV prevalence in infants in our setting, and also the characteristics of hospitalized patients with community-acquired ARI. Even though very few conditions were described, the selection

of clinical situations and the prospective and individualized registration of each case enable the provision of quality data.

CONCLUSIONS

HBoV prevalence in 2011 was 6.8%, a rate lower than in former years, which would justify to continue with the studies about viral circulation to observe what happens during the periods with epidemic outbreaks. In positive cases without an evident co-infection, the diagnosis of pneumonia was predominant without recording severe cases nor complications at discharge. ■

Acknowledgments

To A. J. Roemmers Foundation and to SeCyT, Universidad Nacional de Córdoba.

REFERENCES

1. WHO. Acute Respiratory Infections (Update September 2009). [Accessed on: July 19, 2013]. Available at: http://www.who.int/vaccine_research/diseases/ari/en/index1.html.
2. Allander T, Tammi MT, Eriksson M, Bjerkner A, et al. Cloning of a human parvovirus by molecular screening of respiratory tract samples. *Proc Natl Acad Sci USA* 2005;102:12891-6. *Proc Natl Acad Sci USA* 2005; 102:15712. Errata.
3. Maffey A, Barrero P, Venialgo C, Fernández F, et al. Viruses and atypical bacteria associated with asthma exacerbations in hospitalized children. *Pediatr Pulmonology* 2010; 45:619-25.
4. Vidaurreta SM, Marcone DN, Ellis A, Ekstrom J, et al. M. Acute viral respiratory infection in children under 5 years: Epidemiological study in two centers in Buenos Aires, Argentina. *Arch Argent Pediatr* 2011;109:296-304.
5. Bicer S, Giray T, Çöl D, Erda GÇ, et al. Virological and clinical characterization of respiratory infections in hospitalized children. *Ital J Pediatr* 2013;39-22.
6. Martin ET, Fairchok MP, Kuypers J, Magaret A, et al. Frequent and prolonged shedding of bocavirus in young children attending daycare. *J Infect Dis* 2010;201:1625-32.
7. Ghietto LM, Camara A, Camara J, Adamo MP. High frequency of Human Bocavirus 1 DNA in infants and adults with lower acute respiratory infection. *J Med Microbiol* 2012, 61:548-51.
8. Ghietto LM, Cámara A, Zhou Y, Pedranti M, et al. High prevalence of Human Bocavirus 1 in infants with lower respiratory tract disease in Cordoba, Argentina. *Braz J Infect Dis* 2012;16:38-44.
9. Schildgen O. Human Bocavirus: Lessons Learned to Date. *Pathogens* 2013; 2:1-12.
10. Villa L, Melón S, Suárez S, Alvarez-Argüelles ME, et al. Detection of human bocavirus in Asturias, Northern Spain. *Eur J Clin Microbiol Infect Dis* 2008;27:237-9.
11. Jartti T, Hedman K, Jartti L, Ruuskanen O, et al. Human bocavirus, the first 5 years. *Rev Med Virol* 2012;22: 46-64.
12. Proenca-Modena JL, Pereira Valera FC, Jacob MG, Buzatto GP, et al. High rates of detection of respiratory viruses in tonsillar tissues from children with chronic adenotonsillar disease. *PLoS One* 2012;7:e42136.
13. Meriluoto M, Hedman L, Tanner L, Simell V, et al. Association of human bocavirus 1 infection with respiratory disease in childhood follow-up study, Finland. *Emerg Infect Dis* 2012;18:264-71.
14. Moreno L, Krishnan J, Duran P, Ferrero F. Development and validation of a clinical prediction rule to distinguish bacterial from viral pneumonia in children. *Pediatr Pulmonol* 2006;41:331-3.
15. Collard Brosotti MV, Moreno L, Bujedo E, Marqués I, et al. Prescripción de antibióticos en lactantes hospitalizados con neumonía por virus respiratorio sincicial. *Arch Argent Pediatr* 2008;106:515-7.